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Abstract 
Vibrational spectroscopies, based on Infrared absorption and/or Raman scattering provide a detailed 
fingerprint of a material, based on the chemical content. Diagnostic and prognostic tools based on 
these technologies have the potential to revolutionise our clinical systems leading to improved patient 
outcome, more efficient public services and significant economic savings. However, despite these 
strong drivers, there are many fundamental scientific and technological challenges which have limited 
the implementation of this technology in the clinical arena, although recent years have seen significant 
progress in addressing these challenges. This review examines (i) the state of the art of clinical 
applications of infrared absorption and Raman spectroscopy, and (ii) the outstanding challenges, and 
progress towards translation, highlighting specific examples in the areas of in vivo, ex vivo and in vitro 
applications. In addition, the requirements of instrumentation suitable for use in the clinic, strategies 
for pre-processing and statistical analysis in clinical spectroscopy and data sharing protocols, will be 
discussed. 
Emerging consensus recommendations are presented, and the future perspectives of the field are 
assessed, particularly in the context of national and international collaborative research initiatives, 
such as the UK EPSRC Clinical Infrared and Raman Spectroscopy Network, the EU COST Action 
Raman4Clinics, and the International Society for Clinical Spectroscopy. 
Keywords: Vibrational Spectroscopy, Raman Spectroscopy, Infrared spectroscopy, Translational 
Research, Clinical applications 
  
Introduction: 
The potential of vibrational spectroscopy for biomedical applications has been well established 
through many proof of concept studies over the past decades [1-4]. Due to its unique fingerprinting 
capability, vibrational spectroscopy can play a significant role in histopathology, cytology, biopsy 
targeting, surgical targets, treatment, monitoring and drug studies. However, translation into the 
clinical environment has been slow, and a recent discussion paper has outlined the challenges facing 
progress to the realisation of applications potential [5]. At present, the field of spectral diagnosis is in 
a dynamic evolutionary phase, and a number of key issues remain to be addressed; there has been 
very little progress towards standardisation of either sample preparation, measurement protocols or 
reporting and very few studies on the scale of clinical trials have been undertaken. Although this is an 
exciting time, the lack of consistency in the field may deter investors, hamper product development 
and delay translation. 
Progress towards the objectives of translation requires close collaboration across the range of 
disciplines involved, and a clear identification and understanding of what the un-met clinical needs 
ĂƌĞ ? ĂŶĚ ƚŚĞ ůŝŵŝƚĂƚŝŽŶƐ ŽĨ ĐƵƌƌĞŶƚ  “ŐŽůĚ ƐƚĂŶĚĂƌĚ ? ƚĞĐŚŶŝƋƵĞƐ ?These techniques are based on 
subjective clinical evaluation of morphological changes in cells and/or tissue, and therefore 
consultation with clinicians is imperative, such that improved performance of spectroscopic 
approaches can be compared to consensus standards.  
Understanding the complexities of light interaction with the physically and chemically complex milieu 
of biological samples is, in itself, a challenge. Although vibrational spectroscopy has the potential to 
provide characteristic chemical signatures of disease, the chemical and physical inhomogeneity of the 
samples can confound these signatures, and, although significant progress has been made towards 
understanding scattering processes and dealing with them during data pre-processing routines [6-10], 
there remain questions surrounding interference effects in some measurement modalities [11-14]. 
Standardisation of sample preparation and measurement protocols is also critical, and although 
collective efforts have been made to establish consensus in a research context [15-17], the 
development of protocols for the preparation of cells, tissue and biofluids for clinical spectroscopy 
should be primarily guided first and foremost by the demands of current clinical practice. Validation 
of the robustness of the techniques through inter-ůĂďŽƌĂƚŽƌǇ  “ƌŽƵŶĚ ƌŽďŝŶ ? Žƌ ƌŝŶŐ ƚƌŝĂůƐ ŝƐ ĂůƐŽ
required. 
Data pre-processing and analysis techniques remain the subject of ongoing debate and development, 
in an academic context [18]. However, it has become increasingly important that a consensus on 
optimal data pre-treatment is reached and adopted such that the limits and scope of the data analysis 
can be established and demonstrated in a clinical setting. Equally, the requirement to establish sharing 
protocols for the increasingly complex datasets is rapidly emerging. 
The field of clinical application of vibrational spectroscopy is also enriched by the emergence of novel 
techniques and methodologies which potentially add analytical capabilities and capacity, but also 
introduce new challenges associated with technical aspects as well as with integration into a clinical 
workflow. 
From fundamental research to clinical translation, the field is broadly multi- and interdisciplinary, 
involving as it does fundamental and applied research, chemometrics, biomedical applications and 
ultimately clinical translation. There is, therefore, a critical need for concerted effort which integrates 
all stakeholders, through consortia such as the UK EPSRC Clinical Infrared and Raman Spectroscopy 
Network, the EU COST Action Raman4Clinics, and CLIRSPEC - the International Society for Clinical 
Spectroscopy. This paper reviews the state of play of efforts to realise the translation of vibrational 
spectroscopic techniques into the clinical setting, while addressing the challenges identified, and 
projecting the future perspectives of the field. 
 
State of the Art 
In vivo ? Intraoperative characterisation of tumour resection margins 
Perhaps one of the most striking recent demonstrations of the potential for clinical translation of 
vibrational spectroscopy has been the deployment of fibre based Raman spectroscopy for intra-
operative guidance of brain surgery [19]. Identification of tumour margins is critical to minimise the 
potential for recurrence, and this is particularly difficult for Gliomas, which have poorly defined 
margins. The benefit of minimising the amount of tissue removed is obvious, particularly in the case 
of brain surgery, and therefore the additional guidance of a spectroscopic probe to detect invasive 
brain cancer in situ in real time in patients is potentially invaluable. Jerym et al. demonstrated the use 
of a handheld contact fiber optic Raman spectroscopy probe to distinguish brain cancer (glioma) from 
normal brain in situ. Using state-of-the-art neuro-navigation techniques, MRI was used for 
visualisation and for estimating the location of each Raman measurement on the preoperative images. 
The system was able to measure in vivo spectra and when the data was used to build a boosted tree 
machine learning classification model, using the gold-standard for training, it was possible to show 
that the Raman signals could accurately differentiate normal brain from dense cancer and normal 
brain invaded by cancer cells, with a sensitivity of 93% and a specificity of 91%. The probe enabled 
identification of the diffusely invasive brain cancer cells at cellular resolution in patients with grade 2 
to 4 gliomas. In a further study, the impact of the ambient environment of the operating theatre on 
the performance of the probe system was characterised. [20] In a study of 35 patients, Vaqas et al. 
similarly deployed Raman spectroscopy to analyse tissue at the brain surface, en route to the tumour, 
in superficial and deep tumour zones and resection margins in-vivo during surgery, demonstrating 
that, in comparison to matched core biopsy samples verified by routine histopathology, meningiomas 
and metastases as well as low and high grade gliomas could be identified with high accuracy [21]. 
These and other recent developments of applications of Raman based spectroscopy for improving the 
accuracy of brain tumour surgery have been reviewed by Hollon et al. [22]. In the field of oral cancer, 
Barroso et al. [23] have demonstrated discrimination between oral cancer and healthy tissue based 
on water content of freshly excised tongue specimens, determined by Raman spectroscopy in the high 
wavenumber region. This dramatic signature difference can be used to determine the location of the 
tumor border in oral cancer surgery [24]. 
In vivo ? Endoscopic probes for disease detection 
Fibre based in vivo applications have also been explored for endoscopic gastrointestinal probes. Early 
work by Shim et al. showed the potential [25] but insufficient signal to noise was obtained for early 
diagnosis of malignancies. Huang et al. have been exploring different probe configurations to provide 
diagnostic signals from the lining of hollow organs such as the oesophagus [26]. These multifibre 
probes have been shown to be efficient in terms of light collection, and ongoing work has enabled 
more specific sampling of diagnostically relevant surface signals. The collaborative works of Stone et 
al., have been devoted to developing and testing a confocal probe able to measure signals from only 
the surface 100- 200 Pm of the oesphageal mucosa [27, 28], shown to be the optimum depth for 
identification of early dysplastic changes leading to cancers [29]. This system is currently undergoing 
in vivo trials, funded by UK NIHR. 
A sequence of early feasibility studies have shown that Raman spectroscopy can accurately identify 
metastatic invasion in lymph nodes from the axilla, mediastinum, and head and neck (H&N) using 
Raman microscopic mapping of the cut surface of the nodes [30-32]. Foundation studies in head and 
neck malignancies using NIR Raman have enabled the demonstration that Raman can identify the 
pathology of swollen lymph nodes. Raman spectra can clearly be separated into reactive nodes (those 
swollen from reaction to infection), primary malignancies (lymphomas) and secondary malignancies 
(metastatic squamous cell carcinomas and adenocarcinomas) (90% sensitivity / 86% specificity [33]).  
This performance has been reproduced in the operating theatre, using a low-cost commercially 
available, portable probe-based Raman system to measure the molecular fingerprint of the excised 
sentinel lymph nodes (SLN). Greater that 85% sensitivity and 96% specificity was achieved for 
identification of metastatic nodes. The performance of Raman in the breast SLN feasibility study versus 
other intra-operative results showed Raman measurements to be equivalent to the molecular assay 
approaches, but they require no tissue destruction (allowing for follow up histopathology). 
Furthermore, Raman provided more rapid results and could be applied in vivo [34] 
A smart Raman needle probe has been developed and tested for potential in vivo and ex vivo use, 
capable of measuring Raman molecular tissue signals in <1-2 seconds down a hypodermic needle [35]. 
The hand-held device containing the key optical components is coupled to disposable needle probe 
tips [36]. Initial ex vivo feasibility testing of the technique was performed on excised head and neck 
lymph nodes from 62 patients undergoing surgery. A Principal Components/Linear Discriminant 
Analysis classification model tested using leave-one-patient-out cross-validation showed sensitivities 
and specificities of this first feasibility test exceeding 80% [37].  
For in vivo surgical applications, an interesting study by Aston et al. explored the translation of Raman 
spectroscopic signatures of diseased tissue in to audio signals to provide real-time guidance to 
surgeons without disturbing the visual focus on the patient [38]. 
The field of Raman Spectroscopy for cancer detection and cancer surgery guidance has recently been 
reviewed by Santos et al., demonstrating real progress towards clinical translation of these techniques 
and adoption by the medical community, as well as highlighting challenges [44]. 
In contrast, there have been few demonstrations of in vivo clinical applications of mid  ? IR 
spectroscopy. However, initial studies of the skin have demonstrated that high peak power Quantum 
Cascade Laser (QCL) light sources may allow the measurement of signals below the stratum corneum 
in the skin [45]. Indeed, the goal of the EU MINERVA project is to achieve in vivo MIR molecular 
vibrational spectroscopy [46,47], promising further developments in this aspect of the field. 
Ex-vivo ʹ Spectroscopic Histopathology 
Ex vivo applications of vibrational spectroscopy include analyses of samples taken directly from the 
body for diagnostic purposes, namely tissue biopsies (histological samples), cell biopsies (cytological 
samples) and liquid biopsies (bodily fluids such as blood plasma/serum, saliva, etc.).  
In general, adoption by the medical community is regarded as a key stage of development, and, in this 
context, minimal disruption to the normal workflow is recommended. The adoption of appropriate 
clinical sample preparation and presentation for spectroscopic analytical procedures is therefore 
critical. Ideally, spectroscopic diagnostic techniques should add technical/medical value without 
compromising cost and/or efficiency. In some cases, however, it may be argued that significant 
improvements over an established gold standard may warrant significant changes to currently 
accepted protocols. Such disruptive innovations may not be the most strategic targets for translation 
of the technology into the clinic, however, and so adaptation of the state of the art spectroscopic 
capabilities to the clinical environment should be prioritised, rather than vice versa. The development 
of protocols for the preparation of cells, tissue and biofluids for clinical spectroscopy should therefore 
be guided first and foremost by current clinical practice. 
In the context of surgical procedures, an important application of spectroscopic monitoring has been 
identified as  “ŶĞĂƌƉĂƚŝĞŶƚ ?ƐĐƌĞĞŶŝŶŐŽĨƚŝƐƐƵĞďŝŽƉƐŝĞƐ, taken intra-operatively to guide the surgeon 
in identifying tumour resection margins. Ideally, analysis should be performed on fresh tissue, and 
screening time, including data processing, should be kept to a minimum.  
The incorporation of Focal Plane Array (FPA) detectors in FTIR microscopes has greatly improved data 
acquisition and processing speeds [48], enabling the acquisition of several thousand spectra 
simultaneously. Nevertheless, images from a large area of tissue (cm2) or from a large tissue micro 
array (TMA), often take several hours to acquire. Data analysis and management of these burgeoning 
data sets is also a major problem. Reducing the spectral resolution or reducing the number of co-
added scans can reduce acquisition times but ultimately deteriorates the quality of the data. Recently, 
it has been suggested that the full spectral range is not required for accurate disease diagnosis using 
spectral histopathology [49, 50]. These studies suggest that, once spectral biomarkers are known, it 
may be possible to diagnose disease based on a limited number of discrete spectral features. In this 
context, recent developed high intensity infrared sources, including free electron lasers (FEL), optical 
parametric oscillators (OPO) super continuum and QCLs, have indicated a route towards significant 
further advances in the field. 
QCLs [51] are high intensity, tuneable semiconductor lasers which can emit across the mid infrared 
region of the electromagnetic spectrum. Availability of these high intensity tuneable sources has 
renewed interest in unmultiplexed, scanning infrared spectrometers utilising discrete frequencies 
[52]. In a recent study [53], a QCL imaging system was used to image a large TMA consisting of 207 
breast core biopsies. In addition to rapid imaging at a pixel size of 4.25 x 4.25 Pm2, the high 
magnification optical configuration with a pixel size of 1.36 x 1.36 Pm2 can measure high definition 
images providing a greater level of detail of finer structures not visible using a conventional desktop 
FTIR imaging system that has a pixel size of 5.5 x 5.5 m2 (Figure 1). Using the QCL microscope to collect 
a chemical image of the amide I band, the full TMA composed of a 10x12 array of infrared tiles was 
collected in just 9 minutes. Measurements on the same sample using a state of the art FTIR FPA system 
required approximately 19 hours. Although the direct comparison is unfair, in that the FTIR collects 
the full spectral range and the QCL only collected one discrete frequency, the potential speed 
advantage over FTIR is undeniable, enabling the possibility of high throughput imaging of tissue 
biopsies from a large numbers of patients. One consideration is the speed of collection for each 
infrared tile when multiple frequencies are being collected. FTIR spectroscopy collects all wavelengths 
simultaneous, and sufficient scans are co-added to ensure adequate signal to noise. QCLs are not 
continuous sources, requiring the source to be tuned to the desired wavelength, and data points need 
to be recorded stepwise for each frequency of interest [54]. Despite this, once spectral biomarkers 
have been identified, the instrument could be assigned to collect a limited number of key features, 
enabling high throughput imaging. Recent work has shown that excellent classification of cancerous 
sample can be achieved with as few as 25 frequencies, although classification accuracy starts to drop 
off rapidly as the number of frequencies is reduced. [55] 
 
Figure 1: (a) Expanded view of TMA core (b) FTIR chemical image of amide I, pixel size = 5.5 x 5.5 Pm2. 
(c) QCL chemical image of amide I, pixel size = 1.36 x 1.36 Pm2. [53]. 
Although the speed advantage of QCL discrete frequency imaging is clear, the main focus of research 
has been on throughput rather than accurate disease diagnosis. There are still significant obstacles 
that need to be overcome before such technology can be used routinely. For example, it is still not 
clear how to deal with baseline correction when measuring highly scattering samples such as glandular 
prostate tissue. Acceptance of this new technology will depend on whether high quality infrared 
spectra can be rapidly acquired and still maintain the diagnostic accuracy demonstrated using FTIR 
spectroscopy. Furthermore, given that imaging with a QCL system presents a quantum leap in current 
technology, it needs to be demonstrated that infrared spectra similar to those using a conventional 
FTIR spectroscopic system can be acquired. Despite these exciting developments, large scale trials are 
now required to correctly assess the future of the technology, and its potential in the clinical setting. 
For screening of large sample areas such as tissue biopsies, the required pixel dwell times of the order 
of 0.1 to 10 seconds limits the application of high-resolution Raman microspectroscopy in many areas 
of clinical practice, particularly histological screening. Coherent Raman scattering (CRS) [56] provides 
enhancement of signals by several orders of magnitude and, when applied in a microscopy format, 
benefits from the non-linear nature of the process which confines the signal to a sub-micron focus 
that can be scanned in space, allowing rapid 3D mapping of bio-molecules with sub-micron resolution 
[57]. CRS microscopy can be implemented by recording the coherent anti-Stokes Raman scattering 
(CARS) or stimulated Raman scattering (SRS) signal. While the former has gained popularity for rapid 
screening of large areas, its nonlinear dependence on the number of scatterers means that the 
spectral profiles are not trivially interpreted, and so SRS is favoured for analytical applications [58].  
While other reviews have provided a more comprehensive summary of the technical implementation 
and applications of CRS [59-61], this report aims to highlight the current state-of-the-art in the clinical 
translation of CRS which is paving the way towards its integration into widespread clinical use. The 
applications of CRS microscopies to clinical and biological studies have also been reviewed by Schie et 
al. [62]. Figure 2 shows an example of the use of CARS for the rapid subcellular analysis of Hep2 liver 
cells [62]. CRS techniques also have significant potential to overcome the time limitations of 
conventional histology. Ji et al. [63] demonstrated that SRS microscopy enables rapid, in-situ label-
free acquisition of H&E like images based on the ratio of Raman signals at 2930 and 2845 cmAL1, 
reflecting the different lipid and protein contents. Using this technique, they were able to differentiate 
tumour from non-neoplastic tissue in a human glioblastoma xenograft mouse model and 
demonstrated excellent correlation between SRS and conventional H&E microscopy for detection of 
glioma infiltration. Oringer et al. [64] have demonstrated the clinical translation of SRS microscopy for 
intraoperative tumour margin detection, a significant innovation being the application of a balanced-
detection scheme that allowed SRS to be performed using compact portable fibre lasers and an image-
processing method (stimulated Raman histology, SRH) to convert the SRS signals into virtual H&E 
slides so the existing clinical expertise could be applied to make on the spot decisions, in this 
application, an SRH mosaic of ~ 0.6 x 1.0mm was recorded in ~2.5 minutes. SRH was shown to have 
remarkable agreement with conventional histology, showing an accuracy >92%. Most recently, Francis 
et al. [65] introduced an improvement to narrowband SRS pathology through spectral slicing of 
broadband (femtosecond) pulses. Drawing upon the higher peak power of femtosecond pulses while 
preserving the spectral resolution of picosecond pulses, they demonstrated the same chemical 
specificity as narrowband SRS while achieving a higher signal-to-noise ratio (SNR).  
 Figure 2: (a) CARS image of cellular lipid droplet accumulations in HepG2 cells after the exposure to 
 ? ? ?ʅDŽĨŽůĞŝĐĂĐŝĚ ?K )ĂŶĚ ? ? ?ʅDƉĂůŵŝƚŝĐĂĐŝĚ ?W ) ZĂŵĂŶƐƉĞĐƚƌĂǁĞƌĞƚĂŬĞŶĨƌŽŵƚŚĞŝŶĚŝĐĂƚĞĚ
cellular lipid droplets. The pie charts show the relative amount of oleic and palmitic acid in the 
individual lipid droplets determined from the Raman spectra. The percentile values are plotted below. 
The GC values indicate the amount for OA and PA determined from lipid droplets of millions of cells. 
It can be seen that the values based on Raman spectroscopy and GC are in good agreement. (b) 
Multiphoton image of HepG2 cells. The CARS signal from cellular lipid droplets is in green, and TPEF 
signal of green fluorescence protein expressed in peroxisome in blue. The unnormalized Raman 
spectra for the indicated point are shown below. The peak intensity of the CH2 stretch vibration at 
2854 cmAL1 is 9.8 times lower from peroxisome. [62, reproduced with permission] 
The examples above rely on narrowband (picosecond) excitation, in which the excitation bandwidth 
is confined to the line width of the Raman mode used for contrast. While this scheme provides efficient 
excitation of single Raman bands, spectral mapping requires sequential acquisition of multiple Raman 
modes to acquire morphochemical contrast. However, for spectral imaging, they suffer from 
limitations in motion artefacts between acquisition of images at sequential Raman shifts and the 
speed of laser tuning. Broadband CRS techniques overcome this limitation by using broadband 
(femtosecond) pulses to simultaneously excite multiple Raman bands which are then separated using 
spectroscopic detection. There are many examples of biomedical applications of broadband CRS, and, 
notably Camp et al. [66] recently presented a technique for efficient hyperspectral CRS image 
acquisition over the full spectral range (500  ? 3000cm-1) using intrapulse three-colour excitation to 
achieve high-resolution microspectroscopy with pixel dwell times of a few microseconds. 
Ex-vivo  ? Spectroscopic Cytology 
Cytological screening is commonly employed as a routine preventative measure for early stage disease 
detection, notably for cervical and oral disease [67, 68]. In the case of cervical, screening programmes 
ĂƌĞǁĞůůĞƐƚĂďůŝƐŚĞĚŝŶƚŚĞ “first ǁŽƌůĚ ?ĂŶĚƐŽƐĂŵƉůĞƚŚƌŽƵŐŚƉƵƚŝƐǀĞƌǇŚŝŐŚ ?dŚŝs puts increased 
demands on the cost effectiveness of alternatives or adjuncts to currently employed clinical practice. 
The use of vibrational spectroscopy as an adjunct or alternative to currently employed cytological 
screening methods may be a viable strategic target objective. Particularly in the case of automated 
liquid based cytology methods, it can conceivably be easily integrated into the workflow. Using Raman 
spectroscopy to characterise Thin Prep exfoliated cervical cytological samples, Ramos et al. reported 
sensitivities and specificities of 94% and 95% for Low grade squamous intraepithelial lesion and 84 
and 100% High grade squamous intraepithelial lesion [69]. When calculated according to the 
histological grading system of cervical intraepithelial neoplasia, the sensitivities and specificities 
improved further. Sensitivity to HPV infection has also been reported promising an integrated 
screening for early stage disease [70].  
A limited number of infrared absorption spectroscopy studies have demonstrated the feasibility of 
using oral exfoliated cells. Papamarkakis et al. [71] demonstrated that oral cells could be classified 
according to anatomical region through principal components analysis (PCA). In addition, samples 
from patients with reactive atypical changes or malignancy associated changes were seen to be 
spectrally similar to a sample from a patient with squamous cell carcinoma, rather than samples from 
healthy volunteers. Furthermore, spectral changes were identified in oral cells infected with the 
herpes simplex virus. Further studies from the same group [72, 73] showed that spectra from 
exfoliated cells from the tongues of healthy volunteers could be discriminated from exfoliated cells 
from the tongues of patients with oral dysplasia and cancer. Although there have been few studies of 
exfoliated oral cells, the protocol for cervical spectrocytology should be relatively easily translated, as 
demonstrated recently by Behl et al. [74].   
 
Ex-vivo  ? Liquid biopsies 
Screening of bodily fluidƐ ? “ůŝƋƵŝĚďŝŽƉƐǇ ? )ŝƐĂĨƵƌƚŚĞƌex-vivo application which is currently attracting 
increasing attention and may represent a strategic, achievable target for clinical translation [75]. 
Biofluids offer an ideal diagnostic medium due to their routine use, ease of collection, acceptance by 
patients and the fact that they offer the ability to provide a snapshot of human health (e.g. via systemic 
bodily fluids such as blood (serum, plasma etc.)) and specific tissue function assessment via specific 
biofluids (e.g. bile, sputum etc.) [76] Suspended or dissolved analytes are present in rather low 
concentrations, however, and many studies to date have been performed on dried samples [77, 78].  
Pioneering work by Petrich et al. demonstrated the use of serum spectroscopic diagnostics to be able 
to aid in the triage of patients with acute chest pain discriminating between acute myocardial 
infarction and chest pain of other origin to sensitivities and specificities of 88.5 % and 85.1 % 
respectively [79]. Recent work on serum spectroscopic diagnostics has shown the ability of ATR-FTIR 
spectroscopy to distinguish between a brain cancer serum set of 433 patients (3987 spectra) 
demonstrating the ability to distinguish between cancer vs. non-cancer, metastatic cancer vs organ 
confined, brain cancer severity and organ of metastatic disease with optimum sensitivities and 
specificities between 80.0 and 100.0 % depending upon the question being asked [80]. In addition, 
Raman spectroscopy has recently been shown to be sensitive to disease signature for bodily fluid 
analysis by enabling the discrimination of cirrhotic patients with hepatocellular carcinoma (HCC) and 
without to overall rates of accuracy of 84.5 % to 90.2 % for dried serum drops and 86 % and 91.5 % 
for freeze-dried serum drops [81]. Importantly this study was conducted with a benign inflammatory 
disease background showing the capability to distinguish the malignant disease. 
Translational work by the group from Monash University, based on the use of ATR  ?FTIR spectroscopy 
for the determination of malaria parasitemia in whole blood samples [82], has been recently 
demonstrated in field trials in austere environments proving the robustness and capability of serum 
biofluid diagnostics.  
 
In vitro ʹ Drug screening and Companion Diagnostics 
In vitro studies of cell cultures are plentiful in the literature and are invaluable for the development 
and validation of new measurement technologies, measurement and data processing and analysis 
protocols, and ultimately the exploration of the limits of the techniques in identifying and screening 
biomarkers associated with biological function and dysfunction. The techniques may also provide 
valuable information on, for example, radiation and chemotherapeutic resistance, and present 
opportunities in their own right for potential applications in screening for drug delivery mechanisms 
and efficacy, radiation damage and toxicology [83-88], given the drive for a reduction in the use of 
animal models for evaluating toxicity, due to regulatory developments in both the EU and US (EU 
Directive-2010/63/EU and US Public Law 106-545, 2010, 106th Congress) generally based on the 
ƉƌŝŶĐŝƉůĞŽĨƚŚĞ ?Z ?Ɛ ?to replace, reduce and refine the use of animals used for scientific purposes.  
In this context, the development of 3D cell culture models which better mimic the in vivo environment 
is critical. As an example, multicellular tumour spheroids are commonly used to provide a better model 
of tumour structure [89, 90], in particular to model redox and pH gradients, which can be probed by 
functionalised surface enhanced Raman spectroscopy probes [91]. 
The ability of vibrational spectroscopy to characterise responses of resistant and sensitive cell types 
to drugs opens up potential clinical applications as a Companion Diagnostics (CD) tool, and ultimately 
personalised medicine approaches [92, 93]. Companion diagnostics is a fast-emerging area of in vitro 
ĚŝĂŐŶŽƐƚŝĐƐ ƚŚĂƚƐĞĞŬƐƚŽ ŝĚĞŶƚŝĨǇĂƉĂƚŝĞŶƚ ?ƐƌĞƐƉŽŶƐĞƚŽĂƐƉĞĐŝĨŝĐƚŚĞƌĂƉǇĂŶĚƚŚƵƐŐƵŝĚĞĚŝƐĞĂƐĞ
intervention. Currently, Companion Diagnostic techniques rely on single biomarker detection, but, 
with increasing understanding of disease pathophysiology, advanced techniques need to be 
developed, based on patient profiling and multiplex platforms.  
Farhane et al.[94, 95] demonstrated that Raman spectroscopy could be employed to differentiate the 
respective responses of two different lung cancer lines (A549 and Calu I) to doxorubicin (DOX) 
exposure, indicating that Raman can be employed to help understand cellular resistance pathways. 
Cellular resistance pathways have also been targeted by Yosef et al. [96] and El-Mashtoly et al. [97], 
who used Raman spectral imaging to investigate the oncogenic mutation resistance to epidermal 
growth factor receptor targeting therapy. Specifically, in related studies, colon cancer cells with and 
without oncogenic mutations such as KRAS and BRAF mutations were treated with erlotinib and 
pantinolib, inhibitors of epidermal growth factor receptor, in order to detect the impact of these 
mutations on Raman spectra of the cells as markers of cell resistance. Rutter et al. [98] utilised a cell 
cloning technique to specifically isolate sensitive and resistant cells from a mixed cell population, and 
investigated the difference in response of gemcitabine-sensitive and gemcitabine-resistant CALU-1 
epidermoid lung cancer cells to the commercial drug gemcitabine, using IR spectroscopy. 
Furthermore, Siddique et al. showed that it was also possible to identify differences of nilotinib-
sensitive and nilotinib resistant K562 (a chronic myelogenous leukaemia cell line) cloned cells, using 
both FTIR and Raman microspectroscopies [99]. 
 
Technological Challenges 
In vivo-Fibre probes 
The major technological challenges of in vivo use of vibrational spectroscopies lie in the limited 
penetration depth of mid-IR light in water rich tissues and the relatively weak signals from Raman 
scattering, which can be compromised by background signals from measurement systems, scattering 
and/or fluorescence. Use of near-infrared laser illumination can minimise tissue fluorescence 
contributions, but signals from the silica fibres can dominate Raman spectra without recourse to 
careful optical design and filtration; these signals can be subtracted but the accompanying shot noise 
can not. This may be sufficient to impact on the relatively small Raman signals obtained in the ideally 
short time scales. In vivo measurements need relatively low intensity illumination to ensure no 
thermal damage ensues and short acquisition times (a few seconds or less) to minimise movement 
and patient discomfort. A recent review provides more detail on the strategies to optimise in vivo 
Raman measurements with Raman probes [100]. 
Beyond accessing disease specific molecular signals using fibre probes, the rapidly developing 
technique of deep Raman spectroscopy is emerging as a powerful in vivo tool. Early studies, in 
pioneering the field of deep Raman spectroscopy for biomedical applications, have established the 
basic feasibility of recovering Raman signals (both native and exogenous) from depths of several 
centimetres beneath the surface of animal tissue. This is, by around two orders of magnitude, deeper 
than achievable with conventional approaches such as confocal Raman microscopy. Deep Raman 
sampling involves the use of either transmission (TRS) illumination and collection geometries, or 
spatially offset Raman spectroscopy (SORS), whereby illumination and collection points are spatially 
separated on the outer surface of the tissue [39-41]. Initial work has involved the study of signals from 
substances such as those found in calcified tissues, whereby the signal is distinct from that found in 
soft tissues. Clinically relevant concentrations of calcifications have been detected to depths of up to 
40 mm in animal tissue phantoms (i.e. at near clinically relevant depths; X-ray mammographic 
screening compression ranges from 1.9 to 5 cm thick) demonstrating the basic viability of scanning 
human breasts [42]. This penetration depth was accomplished by dramatically increasing the Raman 
photon gathering rates (by around 100 times) when compared with the first TRS Raman system used 
[43]. This indicates the feasibility of using TRS for non-invasive analysis of breast tissues in vivo. 
One of the most significant requirements of in vivo Raman systems relates to the specific sampling 
volume of the clinical application and sampling method. NIR light is highly scattered and minimally 
absorbed in tissue, and therefore optical designs that do not restrict light collection to the surface 
scattered photons can result in deep signal collection, which may confound results. An example of this 
is when no beam steering or focussing is used in hollow organ endoscopic fibre probes. The relevant 
diagnostic signal may originate from the surface 100-200 Pm in organs such as the oesophagus or 
bladder, and any deeper signals may contain contributions from, for example, normal cell division and 
adipose tissue on the outer organ surface [101]. As an illustration, Figure 3 compares spectra obtained 
using a confocal Raman microscope of bladder biopsy surfaces versus that obtained with a simple in 
vivo probe design of six collection fibres around one illumination fibre. 
 
 
Figure 3: Comparison of Raman spectra from the bladder surface (left) measured using a six collection 
fibres around one illumination fibre probe with no beam steering/focussing at 785 nm ([101] 
reproduced with permission) and (right) Raman spectra measured from bladder biopsy surface using 
a semi-confocal, 830 nm Raman microspectrometer ([102] reproduced with permission). The right 
ŚĂŶĚƐƉĞĐƚƌĂĂƌĞƚŚĞ  ‘ƚƌƵĞ ?ƐƵƌĨĂĐĞƐƉĞĐƚƌĂ ?ŵŽƐƚĚĞŵŽŶƐƚƌĂƚŝŶŐĞĂƌůǇŵĂůŝŐŶĂŶƚĐŚĂŶŐĞƐ ?ǁŚĞƌĞĂƐ
the in vivo spectra show spectra combining the spectral signals from all layers in the bladder wall 
including the adipose tissue surrounding the outside of the bladder wall. This is clear from the highly 
lipid-rich spectra and highlights the importance of designing probes to optimally sample tissue 
regions/volumes of interest. 
 
Ex-Vivo-Spectroscopic Histopathology 
The long standing problem of optical aberrations in FTIR microspectroscopy have been systematically 
addressed [103-108], by introducing a novel, practical, yet elegant, approach to remove scattering 
artefacts, whereby the tissue biopsy is inverted such that the CaF2 window sits between the biopsy 
and objective. Then, an added lens, of the same material as the window, is placed on top of the 
window, centred to the optical axis, to form a pseudo hemisphere. In this way, the rays of light from 
the sample to the objective pass normal to the CaF2 surface and do not refract. The scattering is also 
reduced or removed as the refractive index of the biopsy more closely matches that of the CaF2 than 
it does air. Both these advantages make this added lens approach ideal for measuring biopsies.[106, 
108] The originality and simplicity of this approach has surprised many working in the field, as it was 
thought that optical aberrations are unavoidable when infrared windows were used as a 
substrate.[109] The other important advantages to this added lens approach are the increase in 
magnification and the removal of chromatic aberration, the latter of which would otherwise occur 
when measuring samples through a window, for example imaging of live cells in microfluidic 
devices.[108,110] As such, this method is a state-of-the-art method to acquire high-quality spectra 
without chromatic aberration and scattering. 
High spatial resolution in spectroscopic imaging is vital for revealing histological domains or structures 
on the micrometre scale within biological samples. Until recently, biomedical applications of FTIR 
spectroscopic imaging have mainly been performed in transmission mode but it has been 
demonstrated that FTIR imaging in ATR mode can provide images with much higher spatial resolution. 
In particular, a stringent test for the assessment of the spatial resolution achieved in FTIR 
spectroscopic imaging in both ATR and transmission modes has been presented and it has been 
demonstrated that the true spatial resolution is much lower than what is expected from the projected 
pixel size, which is often used, albeit incorrectly, as a value for spatial resolution. [103, 105, 108] 
Recently micro ATR-FTIR spectroscopic images of living cells have been analysed with disrelation 
mapping which allowed differentiating molecular states of water as well as studying hydration of 
proteins within living cells (Figure 4) [112]. he most recent developments in the area of FTIR 
spectroscopic imaging have been reviewed, where the current state of the art is summarised in 
detail.[106, 108, 113-116] Notably, Kimber and Kazarian specifically highlight improvements in spatial 
resolution and spectral quality through the use of novel added lenses and computational algorithms, 
as well as quantum cascade laser imaging systems, which offer advantages over traditional Fourier 
transform infrared systems with respect to the speed of acquisition and field of view [117].  
 
Figure 4: Two molecular states of water in HEK cell. The disrelation map emphasises the regions where 
water molecules interact with proteins (i.e. hydration). Reproduced from [112]  
In the case of infrared spectral pathology (using either FTIR or QCL microscopes), there are 
technological challenges associated with the most appropriate substrate to use. The obvious choice, 
from the spectroscopists point of view, is to use an infrared transparent substrate such as CaF2 or BaF2, 
both of which also happen to be transparent in the visible, and contribute minimally to Raman spectra 
in the regions of interest for biological samples, and are therefore ideal for microscopy applications. 
The low frequency cut-off for these materials is ~900 cm-1 and 700 cm-1, respectively, meaning that 
most of the important biological spectral features can be recorded. The use of such slides for thin 
tissue sections, measured in standard transmission mode, results in clean spectra with very little 
spectral distortion other than scattering from the sample itself. However, these slides are brittle and 
less robust than glass meaning that there is a significant risk of fracturing in the automated sample 
preparation equipment commonly used in pathology labs. 
An alternative solution is to use infrared reflective microscope slides. These can be stainless steel, 
aluminium or more commonly a glass slide with a reflective coating, such as commercially available 
low e-slides [103], whereupon the measurement is performed in reflection mode (more commonly 
known as transflection mode). The transflection mode effectively doubles the path-length through the 
sample giving better signal to noise ratio for the same thickness and they are relatively inexpensive. 
The cost is a significantly less than that of CaF2 or BaF2 although, Ăƚ ? ? ?ĞĂĐŚ, they are still slightly 
more expensive than conventional glass. The drawback of the transflection mode is that the spectra 
often display frequency dependent non-Beer-Lambert absorption behaviour as a function of 
thickness. Brook et al. [104] first reported this phenomenon explicitly when investigating multilayer 
polymer spheres and found that absorption band intensities did not scale linearly with the thickness 
of the films. They suggested that the variation could be approximated by a squared sinusoidal function 
and proposed that the effect was caused by the electric field standing wave (EFSW), a view supported 
by Filik et al. [13]. The EFSW effect occurs due the interference of the incident and reflected wave. An 
oscillating electric field in the plane of the reflecting surface is very effectively screened such that it 
forces a node at the surface. This means that the strength of the electric field just above the surface, 
within a wavelength or so, is frequency dependent, and therefore different thicknesses of tissue will 
give slightly different intensity spectra even when normalised. The work of Bassan et al. [11, 12] 
conclusively demonstrated the existence of the physical phenomenon and highlighted the 
implications this could have on the analysis of tissue. They showed that the classification accuracy was 
significantly influenced by sample thickness, which was not the case for the same samples measured 
in transmission. This work led to a flurry of papers on the subject, making the case either for or against 
the use of transflection. In the case of the former, several authors suggested that the use of the second 
derivative spectrum essentially negates the non-Beer-Lambert absorption behaviour, while others 
suggested that all tissue studies should be performed in transmission. Recently Lee [105] has cast 
doubt on the EFSW being responsible for the phenomenon, suggesting instead that it is due to a simple 
interference effect between the reflecting surface and the surface of the sample layer. Regardless, it 
is important to note that the non-linear absorption as a function of thickness is not in dispute, and 
that therefore measurements in the transflection mode may compromise diagnostic accuracy. 
A key question in terms of sample preparation for Clinical Applications, both histological and 
cytological, is, can we afford not to work with glass microscope slides? In the research environment, 
many of the proof of concept studies have been conducted with optimised experimental conditions, 
including choice of substrate, to minimise spectroscopic interference in the case of Raman [118], or 
maximise signal by transmission or transflection in the case of IR absorption. [16]. However, routine 
clinical practice, notably, for example, the high throughput Thinprep procedure for routine cervical 
screening, uses standard microscope slides and the cost implications of a change in this practice must 
be considered. 
Based on estimates from the Royal Preston Hospital, Royal Stoke University Hospital and the Coombe 
Women & Infants University Hospital, Dublin, for a population base of 65 million (UK, 2015), a total of 
2.6million tissue biopsies + 10million cytological smears are carried out annually. The current cost of 
Raman grade CaF2 substrates, in orders of 100+, is ~£25, implying an additional annual cost of 
~£65million for analysis of tissue biopsies and ~£250million for routine cytological screening 
programmes, based on spectroscopy. The requirement for sample archiving implies the substrates are 
not reusable, and although it may be argued that widespread adoption of the techniques will, in the 
future, drive down the cost of the spectroscopically optimal substrates and potentially eradicate the 
need for associated consumables such as cellular and tissue stains, any substantially increased running 
cost such as this will not aid in the drive for clinical translation. The implications for adaptation of the 
spectroscopic protocols should therefore be considered.  
Bassan et al. suggested that, for a simple case of distinguishing malignant from non-malignant tissue 
using FTIR transmission, a simple glass microscope slide could be used as substrate [119]. Although 
the low wavenumber cut-off for such a side is 2500 cm-1, implying no access to any of the fingerprint 
region, there is still enough information in the remaining spectrum to get a reasonable classification. 
This work was followed up by Pilling et al who used standard coverslipped H&E stained sections and 
TMA cores, and again demonstrated that tissue pathology and malignant classification could be 
obtained [120]. Figure 5 shows the mean spectra of the different tissue regions 182 H&E stained 
prostate tissue cores measured in the glass transmission window, while Figure 6 shows the false colour 
spectroscopic images of the classified prostate tissue cores. The ability to perform spectro-
histolopathology on glass substrates is important, since this would mean no disruption to the sample 
preparation workflow, thus removing a significant barrier to clinical adoption. It remains to be seen, 
however, if more detailed diagnostic information can be obtained using such a limited portion of the 
spectrum. 
 
Figure 5: Mean spectra of epithelium, stroma, blood and concretion in the glass transmission 
window obtained for 182 H&E stained prostate tissue cores. [120] 
  
Figure 6: False colour image of the classified prostate tissue cores: red = malignant epithelium, 
orange = cancer associated stroma, green = normal epithelium, purple = normal stroma. [120] 
The effect of substrate choice for spectral histopathology by Raman microspectroscopy, has been 
studied by Fullwood et al., highlighting the difficulties of operating with 785nm on glass substrates 
[121]. However, Raman microspectroscopy may be favoured for cytological samples because the 
smaller spotsize/higher spatial resolution enables specific targeting of the nucleus or even nucleoli to 
achieve better classification [122,123]. In development of Raman protocols, choice of wavelength is 
intimately linked with choice of substrate, and the recent comprehensive study of substrates for 
cytological samples and their dependence on commonly used Raman sources by Kerr et al. [118] 
demonstrated that, although not the optimum for spectral quality, the optimal wavelength for glass 
microscope slides is 532nm. At this wavelength, the contribution of the substrate spectrum is 
minimum, and can be routinely subtracted as an independent component by automated routines such 
as Non-negatively Constrained Least Squares Analysis, as previously demonstrated for the so-called 
digital dewaxing procedure [8, 124], or EMSC, as demonstrated by Kerr et al. [125]. 
Recently, it has been demonstrated that readily available and inexpensive aluminium (Al) foil can be 
used as a versatile and suitable substrate for preparing diverse cytology and histology specimens for 
ATR-FTIR, transflection FTIR or Raman spectroscopic measurements.[126] The low and almost 
featureless background spectra of Al foil enables the acquisition of high-quality IR and Raman spectra 
without substrate interference and sacrificing important fingerprint biochemical information of 
biomedical specimen. Furthermore, low-cost stainless steel slides have been reported as potential 
candidate substrates in a routine pathology laboratory setting [127]. These potential new substrates 
would need to be incorporated into a robust protocol acceptable to a diagnostic setting and clinically 
trialled. 
The form of tissue presentation for measurement obviously depends on the clinical applications and 
sample availability. Fresh (frozen) sections are available for near patient intraoperative screening and 
are closest to in vivo tissue architecture and biochemistry. However, fixed sections are preferred for 
histopathology [128], and, for research purposes, analyses of archived tissue libraries may add much 
to understanding disease progression and patient prognosis. Standardised protocols for spectroscopic 
analysis of Formalin Fixed Paraffin Processed (FFPP) are therefore important.  
Notably, it has been demonstrated that it is not necessary to remove the paraffin to obtain usable 
spectral information [124, 129]. Leaving the paraffin in place reduces scattering artefacts in FTIR and 
background scattering in Raman spectroscopy. Recognising the increased variability of the signal in 
Raman microspectroscopy due to the scattering of the polarised source by microcrystalline wax 
residues, ŝŵƉƌŽǀĞĚ “ĚŝŐŝƚĂůĚĞǁĂǆŝŶŐ ?ƉƌŽƚŽĐŽůƐŚĂǀĞƌĞĐĞŶƚůǇďĞĞŶĚĞŵŽŶƐƚƌĂƚĞĚďǇ/ďƌĂŚŝŵĂƚĂů ? ?
for the case or oral tissue [124]. However, the debate over whether to dewax or not to dewax 
continues. It may be argued that greater consistency of spectral information is achieved when sections 
are deparaffinised, and deparaffinising enables histological staining of the sections. However, it has 
been noted and emphasised that the efficiency of the deparaffinisation process, and therefore 
staining procedures, can be very variable and even depend on the tissue pathology [130]. 
Measurement of dewaxed tissue samples increases issues of scattering in both FTIR and Raman 
spectroscopy, although water immersion has been shown to substantially reduce scattering 
background in Raman spectra of tissue samples, due to the optical phase matching effects of the 
aqueous environment [131], while also substantially reducing any photothermal damage, due to the 
heat sinking effect [132]. These effects are less problematic in cytological samples, however. 
Ex-vivo - Spectroscopic cytology 
Sample processing protocols for routine clinical cytological screening are well established for the case 
of cervical screening and have been shown to be compatible with spectroscopic analysis, in the case 
of Raman spectroscopy [69]. Similar sample collection and ThinPrep preparation protocols have been 
adapted for analysis of exfoliated oral cells [133]. In liquid based Cytology applications, operation at 
532nm may imply the need for additional washing protocols. In cytology laboratories, cell suspensions 
prepared for ThinPrep or smear samples are annotated according to a blood scale, whereby 0 indicates 
a clear solution and 3 indicates a bloody sample. Samples presenting a grade 2 or 3 on the blood scale 
are either rejected as being unsuitable or treated using Cytolyte or various solutions to wash the cells 
before preparing the samples. A study by Bonnier et al., demonstrated that even samples graded as 0 
or 1 can present significant influences of trace amounts of blood in their Raman profiles using 532nm 
as source, resulting in a significant variability in spectral profiles of normal samples [134]. 
Haemoglobin is resonant at 532nm and so the Raman contribution is significantly enhanced compared 
to the cellular signal, resulting in the enhanced sensitivity to even trace amounts of blood in the 
sample. The employment of an additional Hydrogen Peroxide (H2O2) treatment of the Thinprep slides 
was demonstrated to eradicate the impact of the blood contributions. The additional washing process 
was seen to have no impact on the cellular classification and could easily be introduced into the 
automated sample processing protocol. 
Operation at such wavelengths raises questions in relation to sample degradation, and an early study 
by Pupples et al., demonstrated that, in live cells, whereas at 633nm negligible photodamage is 
observable, this is not the case at 532nm [135]. Photodamage associated with a photon energy 
dependence is normally associated with photoxidation, however, and the reduced oxygen content in 
fixed cytological samples significantly reduces the impact of photodegradation. In unstained, fixed 
cytological samples, 532nm causes negligible observable damage to the samples over the 
measurement period. However, photodamage due to absorption and/or large fluorescent 
backgrounds due to clinical stains presents a significant problem for the use of Raman spectroscopy 
as an adjunct to cytological screening, although not an issue for IR absorption studies [136]. 
Conventionally stained samples cannot be simultaneously optically and spectroscopically screened, 
suggesting that a fully automated procedure for unstained cell recognition, spectral analysis and 
assessment may be required. In such a procedure, however, registration of cell identification for 
transfer to the pathologist would be required. As an alternative, new stains are required which, while 
rendering the cell morphology visible under white light, do not absorb at the Raman source 
wavelength of 532nm. 
 
Ex-vivo  ? Liquid biopsies 
Biofluids potentially offer the ideal option for a spectroscopic clinical trial due to the advantages 
mentioned previously. However, the analysis of such samples can suffer from problems associated 
with relatively low concentrations of the analyte of interest. Concentration of samples using 
centrifugal filtration devices has been shown to offer an alternative which allows measurement of the 
analytes in the native aqueous environment. Although Raman appears most promising in this context, 
due to the relatively lower contribution of the water, sufficient concentration of the sample also 
allows analysis of the fingerprint region by FTIR spectroscopy [137]. Centrifugal filtration also allows 
fractionation according to molecular weight of the constituent analytes, potentially allowing targeting 
of molecular biomarkers of disease [138].  
Alternatively, the samples can be dried for analysis. However, this introduces chemical and physical 
inhomogeneity into the sample during the drying process, due to the so-called coffee ring effect, 
cracking and gelation patterns, reducing reproducibility and sensitivities [139, 140]. Compositions and 
concentrations vary significantly across the dried droplet, due to different molecular weights and 
relative molecular solubilities, and can cause band saturation in transmission FTIR [26] but Raman 
signals are highly reproducible within the ring. Lovergne et al. performed an infrared 
microspectroscopic imaging study on pure, 2 fold, 3 fold and 4 fold diluted serum (serum diluted with 
deionised water) [141]. The images (Figure 7) highlight the spectral and visible differences between 
the different sample states. It can be seen that the total signal intensity varies within a drop and the 
highest intensity occurs at the drop edge, confirming a gradient of concentration of molecules from 
ƚŚĞĐĞŶƚƌĞƚŽƚŚĞƉĞƌŝƉŚĞƌǇĂƐĂƌĞƐƵůƚŽĨƚŚĞĚƌǇŝŶŐƉƌŽĐĞƐƐ ?ƌĞƐƵůƚŝŶŐŝŶƚŚŝƐ “ĐŽĨĨĞĞƌŝŶŐĞĨĨĞĐƚ ? ?ǁŚŝĐŚ
in the case of human serum is more appropriately known as the Vroman effect [142]. This relationship 
is repeated for the diluted samples with concurrent decrease in overall intensity. It can also be seen 
that major molecular components (proteins-amide I and II 1648 cm-1 and 1542 cm-1, lipids - 1452 cm-
1 and nucleic acids - 1078 cm-1) all follow this same trend. This trend is accentuated in the diluted 
samples. The variability of the composition requires mapping of the droplet profile, increasing 
significantly the screening time, particularly for Raman analysis, although a quicker and simpler regime 
of measuring 5-10 spectra in the ring has been shown to provide reproducible signals. The Vroman 
effect is an unavoidable result of sample preparation but current efforts to reduce this effect have 
focused on the analysis of minute volumes, and the spraying of the biofluid onto a surface. Bulk ATR-
FTIR spectroscopic measurements have been shown to reduce such effects [143], in effect providing 
an average spectrum of the dried droplet. Furthermore, fractionation of human serum by centrifugal 
filtration has been demonstrated to improve the quantitative analysis of low molecular weight 
biomarkers using ATR-IR spectroscopy, for the case of the variation of glucose levels in patient 
samples, such that it is comparable to currently employed clinical analysis techniques [144] and 
quantification of glycine to a level 50 times lower than when using whole human serum. Raman 
spectroscopy has similarly been demonstrated to accurately predict Hepatitis C viral loads in dried 
patient plasma samples [145], although the inherently higher spatial resolution of Raman microscopy 
renders it less favourable for integrating measurements over an inhomogeneous, dried deposit. 
Ultimately, in order to enable clinical translation there needs to be a focus on large population studies 
and procedural and instrumental standardisation to enable regulatory requirements to be met [146] 
 
 Figure 7: ATR-FTIR Serum dilution study of dried drops. Original spectral images were atmospheric 
corrected. Other spectral images were constructed using a single wavenumber. Reproduced from 
[141] 
 
 
In vitro 
For in vitro cytological studies, formalin fixation has been demonstrated to best reproduce the 
characteristics of live cells [147]. Protein coated substrates [148] and 3-D matrices have also been 
explored to improve measurement protocols [149, 150]. Bonnier et al. [151], and Casey et al. [152] 
have demonstrated that caution must be taken when applying conventional 2D cytotoxicity assay and 
drug dosing protocols to cells in a 3D environment, due to differing bioavailabilities of the assay or 
drug. Nevertheless, it is generally accepted that such 3D environments better mimic the in vivo 
extracellular matrix. Addressing the depth of a 3D environment by optical methods is, however, 
challenging. Recent studies have used functionalised nanoparticles to probe physicochemical 
gradients of potential clinical relevance, [153] as well as the effects of radiation therapies in 3D models 
[154] based on the SERS technique. Such multicellular tumour spheroids are relatively small in 
diameter (~500 Pm), however, and thicker tissue mimicking samples may require similar tissue 
processing techniques for analysis [155]. 
 
Data processing and analysis- 
The US NIH (National Institute of Heath) has defined biomarkers as being: 
 “ŝŽůŽŐŝĐĂů ĐŚĂƌĂcteristics that are objectively measured and evaluated as indicators of normal 
biological processes, pathological processes or pharmacologic responses to a therapeutic 
ŝŶƚĞƌǀĞŶƚŝŽŶ ?[156].  
In terms of infrared and Raman spectroscopies, these will be multivariate signatures that allow one, 
for example, to differentiate between patients with disease and healthy controls or in longitudinal 
studies investigate the effect of radiotherapeutic, drug or nutritional intervention on a cohort of 
individuals.   
In the biomarker discovery process, samples are taken from individuals (e.g. a body fluid), and are 
then measured in an unbiased way using spectroscopy. Data preprocessing is applied, and analyses 
are used to elucidate which are the discriminatory peaks or patterns within the data. However, before 
pursuing this path, one needs to consider the intrinsic variations in the experiment. These may be at 
the biological level, the way in which the samples have been prepared and the spectra measured, and 
of course could be related to the instrument itself. Spectral signatures of disease are often subtle 
perturbations to the norm, and therefore any unwanted experimental variability needs to be 
considered before any spectroscopic analyses are performed, as experimental design is key to 
avoiding false discovery. Indeed, there is a significant problem with many clinical studies in which the 
aim is to discover new biomarkers, in part due to poor experimental design and a lack of 
reproducibility [157-160], leading to the current crisis in biomarker discovery [161-164]. 
To affect good design of experiments, is recommended to enlist the help of a (bio-) statistician at the 
planning stage of a project, to ensure that the appropriate individuals are selected so that intrinsic 
factors in human biology are accounted for. These include, but are not limited to: age, gender, 
genotype, reproductive cycle or other diurnal patterns, as well as body mass index [165]. If this is done 
correctly, in case-control studies, the only non-random factor is that which is being testing for and the 
judicious experimental design will have resulted in the correct patients with disease (the cases) being 
carefully matched with healthy individuals (the controls). 
An important consideration in the application of multivariate methods to spectral data analysis is the 
requisite size of dataset. Statistical significance is a critical consideration, and when patient diagnosis 
is the outcome, misclassification has serious consequences. Beleites et al., have carried out a study 
examining the effects of sample size on multivariate classifier models for clinical biospectroscopy 
[166]. It was demonstrated that, while learning curves for dataset sizes common to small scale 
academic studies (2-25) can indicate acceptable performance, the model testing is itself limited by the 
dataset size and that datasets of 75- ? ? ?ƐĂŵƉůĞƐĂƌĞƌĞƋƵŝƌĞĚƚŽƉƌŽĚƵĐĞ  “a good but not perfect 
ĐůĂƐƐŝĨŝĞƌ ? ?
 
Figure 8: The experimental pipeline in a typical spectroscopic experiment.  In all cases this 
pipeline starts with a clinical or biological question and ends up with interpretation of the system, 
which may then be feedback to refine the experiment and to generate (synthesise) new knowledge of 
the biological system. 
Once the spectra data has been collected, the next stage entails the data analysis and this, and the 
above processes, are shown in a flow diagram in Figure 8. The approaches and processes within the 
 ‘ŚĞŵŽŵĞƚƌŝĐƐŽŽ ?ĂƌĞŝŵŵĞŶƐĞĂŶĚƚŚŝƐǌŽŽĐŽŶƚĂŝŶƐŵĂŶǇĚĂƚĂƉƌĞ-processing, data pre-treatment 
and data analysis (processing) algorithms. Several reviews of spectroscopic data processing and 
analysis protocols have been published, for guidance [18, 167]. Many different algorithms are used 
commonly used and these may have to be optimizeĚ ?/ŶƚŚĞĐŚĞŵŽŵĞƚƌŝĐƐĐŽŵŵƵŶŝƚǇ ?ƚŚĞĂĚĂŐĞ ‘ŶŽ
ĨƌĞĞůƵŶĐŚ ?ŝƐŽĨƚĞŶƵƐĞĚĂŶĚƚŚŝƐŝƐďĞĐĂƵƐĞ ?ŝĨŽŶĞĨŝŶĚƐƚŚĞŽƉƚŝŵƵŵĚĂƚĂĂŶĂůǇƐŝƐŵĞƚŚŽĚĨŽƌŽŶĞ
scenario, then it is not guaranteed to translate and work on the next problem. The biological question 
of interest should drive the selection of the most appropriate type of multivariate analyses (MVA) to 
be used and exemplars of these are briefly detailed in Table 1. The computational code for these and 
links to other resources are available to the clinical spectroscopy community here: 
clirspec.org/resources/ 
Table 1: Appropriate data analysis strategies and typical algorithms used to address clinically 
and biologically-driven research questions.  
Data analysis 
approach 
Research question being 
asked 
Algorithm features Chemometric MVA solutions 
Exploratory data 
analysis 
x What can we find out 
about the relationship 
between these samples?  
x No prior 
information is 
required 
x Principal component 
analysis (PCA)  
x Dendrograms 
x Self-organising Map (SOM)  
Experimental design 
Databases containing: 
   (i) Metadata 
   (ii) Spectral data 
Interpretation 
Data collection 
Pre-processing 
Data analysis 
Visualisation 
Iterations of  
assessment*  
& validation
*Most appropriate 
pre-processing and 
multivariate data 
analysis algorithms 
Refine and 
Synthesis 
Statistical validation to 
assess predictive power and 
ability of models to generalise 
Clinical/Biological question 
x e.g., to investigate 
gender or age 
x Unsupervised 
method is used 
Classification of 
samples 
x Can I classify samples 
into different groups?  
x e.g., case-control 
studies 
x Prediction of 
unseen samples 
into groups 
x Supervised learning 
is used 
x Should include 
validation 
x Linear discriminant 
analysis (LDA) 
x Partial least squares-DA 
(PLS-DA) 
x Support vector machines 
(SVM) 
x Random forests (RFs) 
x Neural networks 
Quantitative 
analysis 
x Can spectra be 
correlated with a 
continuous variable 
x e.g., time, age, disease 
status, drug dose 
x Allows quantitative 
prediction of 
unseen samples to 
some continuous 
variable 
x PLS regression 
x Principal component 
regression (PCR) 
x Support vector regression 
(SVR) 
Explanatory 
analysis 
x What are the 
differences in chemical 
or physical state 
between samples 
x e.g., can I find 
vibrational features that 
relate to group 
separation or a 
continuous feature 
x Highlights spectral 
changes as function 
of group 
membership 
x Need to know 
which group each 
spectrum belongs 
to 
x Many algorithms can be 
used: 
x Based on loadings vectors; 
e.g., LDA, PLS-DA, PLSR, 
PCR 
x Feature selection in RFs; 
use of Gini  
x Genetic algorithms (GAs) 
as input selectors for MVA 
 
Critically, during the data analysis phase, statistical validation should be used to assess how robust the 
supervised learning methods (Table 1) have been. This is because, as the name suggests, the analysis 
is being supervised with training pairs of inputs (X-data from infrared or Raman) and outputs (Y-data 
representing the prediction; either categorical for classification or quantitative for continuous 
outputs). Thus, some data not used in model construction should be used to assess how well the 
model has been calibrated. Validation is usually achieved by resampling the data and this is performed 
in several different ways, such as Leave-one-out validation, K-fold validation, Bootstrapping validation, 
External validation, for which new samples are obtained to generate an independent data set to test 
the models, and may be from a different cohort of individuals from a different geographical location 
and can be blind encoded to the investigated for additional rigour. This validation step is critically 
important, and may also be prone to error [168]. 
/ŶĂĐůŝŶŝĐĂůĐŽŶƚĞǆƚ ? ŝƚ ŝƐ ŝŵƉĞƌĂƚŝǀĞƚŚĂƚƐƉĞĐƚƌŽƐĐŽƉŝĐĚĂƚĂŝƐǀĂůŝĚĂƚĞĚĂĐĐŽƌĚŝŶŐƚŽĐůŝŶŝĐĂů  “ŐŽůĚ
ƐƚĂŶĚĂƌĚƐ ? ? ŝŶĐůƵĚŝŶŐ ĂƉƉƌŽƉƌŝĂƚĞ ĐŽŶƚƌŽůƐ ? dŚĞ ƐƵďũĞĐƚŝǀŝǇ ĂŶĚ ƚŚĞƌĞĨŽƌĞ ǀĂƌŝĂďŝůŝƚǇ ŽĨ ƚŚĞƐĞ
standards themselves is often quoted as a driving force for the development of objective technologies 
such as spectroscopy, and therefore the use of consensus is strongly, where possible, and, when not, 
the study should highlight the standard agreement of pathologists for the clinical condition in 
question. Classification models must be validated, and it is insufficient to provide training results only. 
Furthermore, when reporting performance against the gold standard, one should consider using the 
same measures used to compare two or more observers, such as Kappa statistics, and to provide the 
performance demonstrated in the literature for the gold standard discrimination of the pathologies 
under consideration. 
Visualisation of the results of data analysis is essential, as multivariate analyses are used to reduce 
and simplify the data, and it is recommended that any figures are presented as objectively as is 
possible. If scores plots of latent variables are generated from, for example, principal component 
analysis or some discriminant analysis, then biplots should be used of latent variable 1 (LV1) versus 
latent variable 2 (LV2) or LV1 versus LV3, and so on. 2-dimensional projections of a 3-D plot (LV1 v. 
LV2 v. LV3) with colour coding showing the groups to be differentiated could be biased, as these 
scatter ordination plots may have been rotated to show what the researcher wants to see, rather than 
the results being displayed in a completely objective manner.   
Chemical image analysis is also highly visual and can also be performed using infrared or Raman 
spectroscopy, whereby peak areas or LV scores are used to construct images using false-shading from 
some arbitrary low to arbitrary high value. In a nice article by Ashton et al. [169] it was demonstrated 
that different shading approaches can guide the eye to the wrong conclusion. For example, in rainbow 
scaling from red to violet, the average value on this scale is yellow and yet this is a very bright and 
dominant colour. In this scenario, the eye can be falsely drawn into thinking this is significant, when 
clearly it is not. A much better approach would be to use a more linear colour gradient from, for 
example, blue for low values to yellow for high values of each pixel. 
 
Data Sharing- 
The reasons to share data are many and varied. Take, as an example, an experiment where tissue 
biopsies are analysed to see whether it is possible to determine if cancerous tissue is present [120]. 
Serial sections of tissue are stained with haematoxylin and eosin (H&E), or undergo IR image analysis. 
Some of the H&E sections will be annotated by a pathologist to determine cancerous regions. Spectra 
from corresponding regions of the IR analysed section are then used to develop a model for detection 
of the cancer. The pathologist acts as a gold standard for identification of the cancerous tissue and the 
ŵŽĚĞůďƵŝůĚŝŶŐĞǆĞƌĐŝƐĞĂŝŵƐƚŽƌĞƉůŝĐĂƚĞƚŚĞƉĂƚŚŽůŽŐŝƐƚ ?ƐĚĞƚĞƌŵŝŶĂƚŝŽŶ ?
The IR data acquired during this experiment could also be used in later experiments, for example to 
see whether different pathologists identify slightly different regions of the tissue, thereby changing 
the model produced, or used in the identification of tissue architecture. All pathologists will follow the 
relevant guidelines, but classification of cancer is not a straightforward issue. Therefore, it may be 
interesting to reinterpret existing data in the light of evolving pathology guidelines.  
The clinical translation of vibrational spectroscopies will result in a range of non-ideal environmental 
conditions such as temperature, humidity, sample thickness, sample storage conditions, substrate 
quality and variation, magnification etc. The requirement for high throughput will also impact signal-
to-noise characteristics. Having archival data with a range of provenance will aid identification of 
robust algorithms.  
An increasing number of funders require data, produced as a result of their financial input, to be made 
openly available. On a more prosaic level, a field able to indicate the extent and usefulness of its data 
can help to justify the financial and resource outlay of the past, secure continuing investment and 
foster a growing community.  
Data sharing has some practical considerations; what to share and where to share. Along with many 
other fields, the community of clinical IR and Raman spectroscopists currently has no domain-specific 
repository. Most journals offer a small amount of space in which to store information supplementary 
to an article, but only subscribers to the journal can access this data. To cater for the long tail of 
science, general purpose data repositories have emerged, examples of which include figshare [170], 
Mendeley Data [171] and Zenodo [172]. Some journals now offer to host large volumes of data, 
relating to Open Access publications [173] and many universities and research institutes are 
establishing their own repositories to host data from their researchers. All these repositories will 
allocate a unique digital object identifier (DOI) [174] to the data set, enabling a permanent indicator 
to the location of tŚĞĚĂƚĂ ? ‘ƉĞƌŵĂŶĞŶƚ ?ƚǇƉŝĐĂůůǇŝŵƉůǇŝŶŐŝŶĞǆĐĞƐƐŽĨ ? ?ǇĞĂƌƐ ? 
In order to fill the gap between a domain-specific repository and widely scattered data stores, a 
Community has been created on the Zenodo platform for clinical IR and Raman data [175]. The 
underlying Zenodo repository allows for an unlimited number of data sets per user, each up to 50 GB 
in size, larger data sets being accommodated on request. There is no fee for contributing data, or 
downloading it. Embargo periods are available on this, and most other platforms, to enable the data 
owner time to publish additional papers before the data is released openly.  
In determining what to share, it can be helpful to divide the available data into broad categories: 
spectra, including hyperspectral images; metadata, which is the information describing the sample, 
experiment and the workflow executed; and computer code used to process the spectra. These 
categories will be taken in turn.  
Spectra and hyperspectral image files should be stored in their raw form in the proprietary format of 
the instrument vendor. These files contain the most information that it is possible to collect regarding 
the experiment performed. In addition, to cater for those without the software able to access these 
files, a number of de facto standards can be used. Open standards available to the IR and Raman 
community include JCAMP-DX [176, 177], SPC and HDF5 [178], and some vĞŶĚŽƌƐ ?ƐŽĨƚǁĂƌĞǁŝůůĞǆƉŽƌƚ
data to files in these formats directly. The reason for sharing in both proprietary and open formats is 
to maximise the information content of the resource. If there is only capacity for one type, then the 
open version is preferred. If data size becomes an issue, file compression can be used.  
dŚĞƐƉĞĐƚƌĂĂŶĚŚǇƉĞƌƐƉĞĐƚƌĂůŝŵĂŐĞƐĂƌĞǁŚĂƚŽŶĞŵŝŐŚƚƵƐƵĂůůǇĐŽŶƐŝĚĞƌƚŽďĞ ‘ĚĂƚĂ ? ?ŚŽǁĞǀĞƌ ?ŽŶ
their own they lack the context to be useful. Metadata, sometimes described as data about data, 
supplies that context and describes all parameters involved in the experiment lifecycle. The various 
stages that the experiment comprises can include the following:  
x Patient information such as gender, age, the organ of interest, biobank identifiers and other 
ethically restricted information; 
x Sample type; tissue, bodily fluid, bone; 
x Sampling method; in vivo, ex vivo, orientation of sample in original organ 
x Time and state of sampling; before/after drug treatment 
x Sample preparation; storage, filtration, fixation and embedding processes; 
x Experiment performed; instrumental parameters and acquisition conditions; 
x Experiment repetition; biological replicates, or technical replicates; 
x Data treatment; algorithms and parameterisation of quality tests and other operations.  
Some of this information will be captured in the research paper, but the level of detail can be 
important [179] and therefore as much information as practically possible should be included. Some 
information will be captured in standard operating procedures (SOP) which should be stored 
separately, in an open manner, and referred to via a DOI. Deviations from a recorded SOP should be 
documented and released as a new SOP, referencing the original to highlight the modifications. The 
separation of the SOP(s) from a given experiment allows for re-use of the protocol in a different 
context. SOPs for clinical IR and Raman can be uploaded to the CLIRSPEC Zenodo Community 
repository mentioned above.  
Where patient data is restricted for ethical reasons, it may be possible to store identifiers such that 
other researchers, granted access to the controlled information, will be able to match the same 
patients to their spectroscopic data. Care should be taken to abide by any data protection guidelines 
in force.  
The methods employed for data preprocessing and analysis should be recorded, together with all 
relevant parameters such as the window size for differentiation, the number of principal components 
for PCA denoising, or the discrimination levels for quality testing. The computer code used to perform 
these steps should be identified so that the end-user can repeat the steps on this, or other, data, or in 
a different order. The version number of software should be recorded. This is particularly important 
for regularly updated, open source computer code; for example refs [180-185]. In-house computer 
codes should be stored in version controlled source code repositories such as GitHub [186] or 
Bitbucket [187]. These resources record versions of the code as it evolves. Users of the GitHub 
platform can automatically generate a DOI for a software release on the Zenodo platform [188], 
allowing for a historical snapshot with a unique identifier. Similar to the case for SOPs, software should 
be stored separately from the data, with unique identifiers supplied relating the two entities.  
When re-using, data it is important to recognise any restrictions imposed by the original owner. These 
are listed in the form of licence conditions attached during deposition. For spectroscopic data, 
metadata and SOPs the Creative Commons CC-BY licence is recommended [189]. This allows the user 
to adapt and redistribute the data, but requires that appropriate credit is given to the original owner, 
and any modifications identified. For software, a permissive licence such as the GNU Lesser General 
Public License (LGPL) [190] is preferred. This allows for re-use for any purpose, but requires 
acknowledgement of the original author, and that any modified versions of the code be released under 
an equally liberal licence [191]. In order for a researcher to re-use data, they must first find it. It is 
recommended that any papers making use of the data, including its original creation, cite the DOI of 
the storage point. This is a requirement if published under a CC-BY licence. The repository should also 
list the DOI of any papers making use of the data. This cross-linking will give the data as much publicity, 
and therefore potential for re-use, as possible.  
The (meta)data generated has the potential to assist in the growth and understanding of the clinical 
IR and Raman field, and the sharing of data, simply another form of sharing expertise and knowledge. 
It loses value, however, if the appropriate information about patient cohort, instrument calibration, 
pre- and post processing parameters etc. are provided. Journal editors, reviewers and indeed readers 
should strive to enforce the requirement for the provision and deposition of all such data, since, 
without it, the knowledge content of the research is greatly limited.  
 
Outlook: Clinical Translation 
Most spectroscopic analysis and imaging systems are state-of-the-art research grade instruments 
designed for the research laboratory and often come with "bells and whistles" appropriate for a 
range of different analytical applications. They are analytical instruments rather than purpose built 
medical diagnostics instruments and their designs are not necessarily compatible with a clinical 
environment. It is clear that many of the potential functions are simply not required for many clinical 
applications.  
As they address many potential analytical applications, the market for such instrumental technologies 
is broad, ranging from academic research, to food science, the pharma industry, and forensic science, 
to name but a few application areas. Instrument manufacturers are therefore, by and large, reluctant 
to dedicate instrument design to the specific area of clinical/medical diagnostics, in which the 
techniques have not yet been firmly established.  
It is worth noting that, currently, commercially available spectroscopic instrumentation has been, by 
and large, optimised for sophisticated analysis of chemically pure materials. Perhaps a significant step 
towards clinical translation may be the design of instrumentation which is specifically tailored to 
accommodate the chemical and physical inhomogeneities and complexities of clinical samples. An 
example of such an approach could be the inclusion of integrating collection optics as default, to 
minimise scattering losses [192]. In the case of Raman spectroscopy for in vivo applications, the 
situation is somewhat further advanced. RiverD International B.V. in the Netherlands has developed 
Raman instrumentation specifically for in vivo skin measurement, although applications for the study 
penetration and transdermal delivery of topically applied materials are predominantly promoted 
[193]. Furthermore, Raman probes have been developed specifically for in vivo clinical applications, 
although each research group has their own design. 
It is important to ask "what is the minimum quality of instrumentation and the minimum number of 
functions/flexibility that is required for a clinical spectroscopy system/microscope". This has not yet 
been evaluated, since it very much depends on the specimen under study. The requirements will be 
different for applications involving tissue, cells, biofluids, whether the instrument is to be situated in 
an operating theatre, a pathology laboratory, or indeed employed for remote field trials, whether the 
samples will be frozen or not etc.  
dŚĞ ƋƵĞƐƚŝŽŶ ŽĨ  “,Žǁ ŐŽŽĚ ŝƐ ŐŽŽĚ ĞŶŽƵŐŚ ? ? ? ŝƐ ŽŶĞƚŚĂƚ ŚĂƐ ďĞĞŶ ĞǆƚĞŶƐŝǀĞůǇ ĚŝƐĐƵƐƐĞĚ ďǇ ƚŚĞ
community over the past decade. Some of the deliberations are summarised in, for example the 
editorials of the special issues of Analyst, Optical Diagnostics, derived largely from panel or group 
discussions of the SPEC 2014 and SPEC 2016 conferences [5, 194]. The Faraday Discussions (2016) on 
Advanced Vibrational Spectroscopy for Biomedical Applications includes aspects of clinical translation, 
but also many of the other more technical consideration [115]. It is clear that there is no single answer 
to the question, and that required performance depends on the application, and critically clinical 
demand. In applications such as evaluation of resection margins in neurosurgery, there is no 
alternative comparator and the value to the patient is in estimable. In routine screening applications 
such as cervical cytological screening, current protocols are well established, and improved 
performance must be more closely scrutinised. Justification of improved performance must also 
consider, for example, clinical workflow and health economics. Indeed, an indication of some progress 
in the field is the evolution of the language used by the spectroscopy community, which demonstrated 
an increased understanding of clinical requirements. The patient perspective is of course of critical 
importance [195] 
It is also important that the robustness of the techniques is evaluated, in terms of reproducibility of 
the diagnostic performance of individual instruments and comparison of different instruments, and 
operators, sites, etc.. In recent years, a limited amount of attention has been paid to such 
considerations, and notably, Isabelle et al. conducted a UK based multi-centre trial of Raman spectral 
mapping of oesophageal cancer tissues [196]. They developed a classification model to discriminate 
between adenocarcinoma (AC) and non-cancerous intraepithelial metaplasia (IM) oesophageal tissue 
samples, measured on three different Raman instruments in three different locations. Spectra were 
corrected using system transfer spectral correction algorithms including wavenumber shift (offset) 
correction, instrument response correction and baseline removal which minimized the instrument and 
sample quality variations within and between the instrument sites. Notably, strict calibration 
protocols were also required (around 0.2 cm-1 peak reproducibility). The EU COST Action 
Raman4clinics is currently (sept 2016- sept 2018) undertaking a series of more extensive ring trials 
which will encompass laboratories across Europe [197].  
It is clear that significant advances towards demonstration of the potential of vibrational spectroscopy 
for clinical applications continue to be made. Many of the technical challenges have been and/or are 
being addressed, and emerging technologies such as QCL based IR microscopy and nonlinear Raman 
techniques are poised to dramatically improve the acquisition timescales. Much of the proof of 
concept research is performed on within an academic context, and such research has addressed many 
of the fundamental challenges of dealing with the interaction of light with complex media, analysis of 
the complex data sets, and many advances in the associated technologies have been made. However, 
such academic research, by its nature, requires innovation on the timescale of postgraduate 
qualifications (3-4 years). Within this context, standardisation of protocols and methodologies is 
difficult to implement, and, in general, translation requires a significantly longer timescale to affect 
[198]. Increasingly, however, the academic community has been working ever closer with clinical and 
instrument manufacturer partners, towards a better understanding of the clinical needs and 
identification of realistic strategic target applications. In this context, the importance of collaborative 
frameworks such as the UK EPSRC Clinical Infrared and Raman Spectroscopy for Medical Diagnosis 
Network, and the EU COST Raman4Clinics Action are invaluable. Much of the current EU wide 
community was brought together through the EU FP6 SSA DASIM, which led to significant advances in 
understanding and addressing issues of resonant scattering in IR spectroscopy [6, 7, 8]. It is hoped that 
the formalism of the International Society for Clinical Spectroscopy (www.clirspec.org) will continue 
to facilitate progress in a similar fashion, promoting consensus of sample presentation and 
measurement as well as data processing protocols, towards the translation of spectroscopy into the 
clinical environment, for the general benefit of patients, to improve patient diagnosis and prognosis. 
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